Immunovant Inc (IMVT) Peer Comparison
$41.20
$-2.62
(-5.98%)
As on 28-Aug-2026 16:00EDT
Market cap
$8,510 Mln
Revenue (TTM)
$7 Mln
P/E Ratio
--
P/B Ratio
12.3
Div. Yield
0 %
Edit
| Immunovant Inc (IMVT) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
8,510 | 16,765 | 16,261 | 13,492 | 11,994 |
Revenue ($ Mln) |
7 | 2,782 | 1,054 | 2,436 | 670 |
Net Profit ($ Mln) |
-538.22 | 491.50 | 755.85 | 860.62 | -319.95 |
Net Margin (%) |
-7,585.86 | 17.67 | 71.69 | 35.33 | -47.79 |
RoE (%) |
-62.53 | 110.09 | -- | 42.98 | -71.14 |
Price to Earnings |
-- | 35.25 | 19.00 | 17.40 | -- |
Price-To-Book |
12.31 | 39.29 | 9.76 | 7.42 | 26.87 |
Income Statement ($ Mln)
| Immunovant Inc (IMVT) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 2,530.23 | 691.71 | 2,320.13 | 829.45 |
|
Cost of Revenue
|
0.41 | 1,769.62 | 103.18 | 83.70 | 23.93 |
|
Gross Profit
|
-0.41 | 760.62 | 588.53 | 2,236.43 | 829.45 |
|
Operating Expenses
|
532.90 | 225.68 | 719.42 | 1,364.24 | 731.10 |
|
Operating Profit (EBIT)
|
-532.90 | 534.94 | -130.89 | 872.19 | 98.35 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-505.39 | 542.38 | -204.26 | 941.21 | 51.53 |
|
Provision for Tax
|
0.22 | 91.25 | 14.78 | 158.64 | 21.42 |
|
Profit after Tax (Net Income)
|
-505.61 | 451.12 | -219.03 | 782.57 | -1.63 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Immunovant Inc (IMVT) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
852.59 | 459.07 | -162.75 | 2,161.32 | 466.05 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
0.55 | 172.65 | 395.83 | 277.46 | 686.39 |
|
Current Liabilities
|
104.42 | 1,343.75 | 1,068.94 | 405.64 | 195.49 |
|
Total Liabilities
|
957.57 | 1,975.47 | 1,302.02 | 2,844.42 | 1,385.30 |
Assets ($ Mln)
| Immunovant Inc (IMVT) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
8.75 | 985.85 | 193.50 | 1,401.13 | 434.66 |
|
Current Assets
|
948.82 | 989.62 | 1,108.51 | 1,443.29 | 950.64 |
|
Total Assets
|
957.57 | 1,975.47 | 1,302.02 | 2,844.42 | 1,385.30 |
|
Total Debt*
|
0.07 | 250.50 | 871.41 | 173.04 | 366.28 |
|
Net Current Assets
|
844.40 | -354.12 | 39.59 | 1,037.65 | 755.15 |
Cashflow ($ Mln)
| Immunovant Inc (IMVT) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-407.31 | 713.22 | 51.77 | 884.27 | 179.55 |
|
Cash Flow from Investing Activities
|
-0.01 | -31.14 | -8.15 | 350.44 | -129.29 |
|
Cash from Financing Activities
|
595.76 | -860.39 | 34.89 | -969.59 | 74.01 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Immunovant Inc (IMVT) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-64.81 | 53.56 | -30.01 | 32.82 | -0.17 |
|
ROE (%)
|
-64.82 | 70.23 | 163.18 | 35.53 | -0.50 |
|
ROA (%)
|
-58.32 | 22.13 | -17.65 | 27.02 | -0.13 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | 17.83 | -31.67 | 33.73 | -0.20 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Immunovant Inc (IMVT) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.20 | 0.90 | 0.07 | 232.58 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-22.17 | 11.56 | 42.07 | 50.13 | 99.73 |
|
EPS Growth (%)
|
0.09 | 0.23 | 0.44 | 0.50 | 1.00 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Immunovant Inc (IMVT) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-10.01 | 36.06 | -59.76 | 15.79 | -2,869.63 |
|
Price / Book Value
|
5.94 | 35.44 | -80.42 | 5.72 | 10.04 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-8.23 | 28.08 | -121.54 | 12.44 | 25.04 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Immunovant Inc (IMVT) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.55 | -5.35 | 0.08 | 0.79 |
|
Short term debt to equity ratio
|
0.00 | 0.05 | -2.99 | -- | 0.10 |
|
Current Ratio
|
9.09 | 0.74 | 1.04 | 3.56 | 4.86 |
|
Quick Ratio
|
-- | -- | 0.76 | 3.50 | -- |
|
Interest Coverage
|
-- | -- | -1.64 | -- | 1.58 |
Operating Efficiency Ratios
| Immunovant Inc (IMVT) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 15.89 | 22.79 | 12.37 | 0.82 |
|
Asset Turnover
|
0.00 | 1.24 | 0.56 | 0.80 | 0.66 |
|
Receivable days
|
-- | 50.42 | 85.52 | 43.48 | 1.50 |
|
Inventory Days
|
-24,125.88 | -- | 1,056.70 | 96.17 | -- |
|
Payable days
|
11,250.86 | 6.26 | 331.01 | 147.97 | 221.81 |
|
Cash Conversion Cycle
|
-- | -- | 811.21 | -8.32 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
